# Evaluation of Diagnostic Performance of VisioCyt® Test, in Case of Suspicion of Urothelial Bladder Tumors

> **NCT02966691** · NA · COMPLETED · sponsor: **Vitadx** · enrollment: 1360 (actual)

## Conditions studied

- Bladder Cancer

## Interventions

- **OTHER:** VisioCyt® diagnostic test

## Key facts

- **NCT ID:** NCT02966691
- **Lead sponsor:** Vitadx
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-24
- **Primary completion:** 2020-12-31
- **Final completion:** 2021-01-16
- **Target enrollment:** 1360 (ACTUAL)
- **Last updated:** 2022-01-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02966691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02966691, "Evaluation of Diagnostic Performance of VisioCyt® Test, in Case of Suspicion of Urothelial Bladder Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02966691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*